The net result: reduced appetite (GLP-1), improved insulin action and fat metabolism (GIP), plus increased energy expenditure (glucagon)
Here is a detailed analysis that compares and contrasts the distinct properties of both peptides
GIP, glucose-dependent insulinotropic polypeptide, improves insulin sensitivity and plays a direct role in lipid metabolism
The role of research peptides Because retatrutide is not yet approved, researchers who want to study it currently rely on research-grade peptide
14, 2025 Northwestern, Why do so many people stop taking weight-loss drugs within a year?, Nov
In a separate Phase 2 type-2-diabetes trial, retatrutide lowered HbA1c by up to 2.02 points and cut body weight by about 16.9% at 36 weeks outperforming the GLP-1 agonist dulaglutide[2]